Contents

REVIEW
5094 Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer
Zhou B, Zhang SR, Chen G, Chen P

ORIGINAL ARTICLE

Basic Study
5104 Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly

Retrospective Cohort Study
5125 Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study

Retrospective Study
5138 Machine learning-based decision tool for selecting patients with idiopathic acute pancreatitis for endosonography to exclude a biliary aetiology

Clinical Trials Study
5154 Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis
Chen TT, Lv JJ, Chen L, Li M, Liu LP

Observational Study
5166 Lowering the threshold of alanine aminotransferase for enhanced identification of significant hepatic injury in chronic hepatitis B patients
Yu HS, Jiang H, Li MK, Yang BL, Smayi A, Chen JN, Wu B, Yang YD

CORRECTION
5178 Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”
Roy S, Dhaneshwar S
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Konstantinos Triantafyllou, MD, PhD, FEBGH, Full Professor, Hepatogastroenterology Unit, Second Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens 12462, Greece. ktriant@med.uoa.gr

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.
Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”

Supriya Roy, Suneela Dhaneshwar

Abstract

Key Words: Ulcerative colitis; Crohn’s disease; Pouchitis; Dysbiosis; Microbiota; Inflammation

Core Tip: This manuscript is to add a “correction note” to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”.

Citation: Roy S, Dhaneshwar S. Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”. World J Gastroenterol 2023; 29(35): 5178-5179

URL: https://www.wjgnet.com/1007-9327/full/v29/i35/5178.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i35.5178
TO THE EDITOR


In this article, a correction note is to be added[1]. The corresponding author received a mail from Dr. Claudio De Simone sharing his concern about a probiotic formulation VSL#3 which is mentioned in this review article. Dr. Claudio wishes us to publish a corrigendum. It is an earnest request that please incorporate the following correction note and publish a corrigendum regarding the same.

Correction note: This review article includes references to several studies that investigated a probiotic formulation formerly marketed as VSL#3 which is currently, generically referred to as the “De Simone Formulation”. It is important to note that the current product marketed as VSL#3 differs from the De Simone Formulation as also stated by the federal court of Maryland in the Civil Action, No. TDC-15-1356. They are distinct probiotic formulations with different compositions and characteristics. Currently, the De Simone Formulation is accessible under Vivomixx (in Europe) and Visbiome (in the United States) brand names.

FOOTNOTES

Author contributions: Dhaneshwar S conceived the idea and designed the review article protocol, edited the final draft of the manuscript; Roy S collected the data and wrote the paper; and all authors reviewed and approved the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: India

ORCID number: Supriya Roy 0000-0002-8676-5113; Suneela Dhaneshwar 0000-0001-7646-642X.

S-Editor: Fan JR
L-Editor: A
P-Editor: Fan JR

REFERENCES
